Beta 2-glycoprotein I for binding of anticardiolipin antibodies to cardiolipin

Dissociation of yeast ribosomes; The effects of hydrostatic pressure and KCl.

Molecular biology reports·2013

Calcium-activated and apoptotic phospholipid scrambling induced by Ano6 can occur independently of Ano6 ion currents.

Cell death & disease·2013

Direct inhibition of phospholipid scrambling activity in erythrocytes by potassium ions.

Cellular and molecular life sciences : CMLS·2008

Microparticles adhere to collagen type I, fibrinogen, von Willebrand factor and surface immobilised platelets at physiological shear rates.

British journal of haematology·2007

Anticoagulant and antithrombotic properties of intracellular protease-activated receptor antagonists.

Journal of thrombosis and haemostasis : JTH·2006

Biomechanical evaluation of scapular girdle in patients with chronic arm lymphedema.

Lymphology·2006

The 2026 report of the Lancet Countdown on health and climate change: a decade of escalating health harms and a decisive moment for all.

Lancet (London, England)·2026

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Lancet (London, England)·2026

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Lancet (London, England)·2026

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

Lancet (London, England)·2026

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Lancet (London, England)·2026

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

Lancet (London, England)·2026

Scleroderma-Like Phenotype in a Patient With Transthyretin Cardiac Amyloidosis and Acromegaly: A Triple Diagnostic Challenge.

Cureus·2026

In-vitro exposure to mercury chloride, with and without n-3 long chain polyunsaturated fatty acids, on the Th17-associated immune response in peripheral blood mononuclear cells from systemic lupus erythematosus patients.

Journal of immunotoxicology·2026

Mesenchymal Stem Cell Therapy for Multiple Sclerosis: Harnessing Immunological Properties.

Biomolecules & therapeutics·2026

Molecular underpinnings of rheumatic diseases and emerging therapeutic concepts.

Nature·2026

Adaptive immune plasticity in MASH: Functional states, pathological consequences, and regulatory mechanisms.

Hepatology communications·2026

Imaging of myositis: An overview and update.

Seminars in nuclear medicine·2026

Beta 2-glycoprotein I for binding of anticardiolipin antibodies to cardiolipin

Related Experiment Videos

Related Concept Videos

Dissociation of yeast ribosomes; The effects of hydrostatic pressure and KCl.

Calcium-activated and apoptotic phospholipid scrambling induced by Ano6 can occur independently of Ano6 ion currents.

Direct inhibition of phospholipid scrambling activity in erythrocytes by potassium ions.

Microparticles adhere to collagen type I, fibrinogen, von Willebrand factor and surface immobilised platelets at physiological shear rates.

Anticoagulant and antithrombotic properties of intracellular protease-activated receptor antagonists.

Biomechanical evaluation of scapular girdle in patients with chronic arm lymphedema.

The 2026 report of the Lancet Countdown on health and climate change: a decade of escalating health harms and a decisive moment for all.

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

Scleroderma-Like Phenotype in a Patient With Transthyretin Cardiac Amyloidosis and Acromegaly: A Triple Diagnostic Challenge.

In-vitro exposure to mercury chloride, with and without n-3 long chain polyunsaturated fatty acids, on the Th17-associated immune response in peripheral blood mononuclear cells from systemic lupus erythematosus patients.

Mesenchymal Stem Cell Therapy for Multiple Sclerosis: Harnessing Immunological Properties.

Molecular underpinnings of rheumatic diseases and emerging therapeutic concepts.

Adaptive immune plasticity in MASH: Functional states, pathological consequences, and regulatory mechanisms.

Imaging of myositis: An overview and update.

Beta 2-glycoprotein I for binding of anticardiolipin antibodies to cardiolipin

Related Experiment Videos

Related Concept Videos

Related Articles